Suot. For, PTO-1449

Sheet

## INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

2

1

Docket Number 106941.190 Application Number 09/760,506

Applicant
Charlotte Kensil

Filing Date

Group Art Unit

01/12/2001

1632

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CQ	4,469,863	09/04/84	Ts'o et al.			11/12/80
vc,	4,522,811	06/11/85	Eppstein et al.			07/08/82
1001	5,023,243	06/11/91	Tullis			05/15/89
100- 12	5,057,540	10/15/91	Kensil et al.			08/27/90
37	5,443,829	08/22/95	Kensil et al.			09/24/93
DEMARK	5,583,112	12/10/96	Kensil et al.			07/02/92
<b>V</b>	5,977,081	11/02/99	Marciani			05/20/98
	·					
						:- :- :

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER					YES	NO
CQ	WO 95/26204	05/10/95	WIPO				
CQ	WO 98/40100	17/09/98	WIPO				

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
	٠,	AGRAWAL, S., "Antisense oligonucleotides as antiviral agents", <i>Trends Biotechnol</i> 10:152 –158 (1992)
ca		AGRAWAL, S. et al., "Oligodeoxynucleoside phosophoramidates and phosphorothioates as inhibitors of human
	<u> </u>	immunodeficiency virus" Proc. Natl. Acad. Sci USA,85:7079-7083 (1988)
1 .		BEAUCAGE, S.L. et al., "Deoxynucleoside phosphoramidites –A new class ofkey intermediates for
	•	deoxypolynucleotide synthesis", Tet. Let. 22:1859-1862 (1981)
		BOGGS, Russell T., et al., "Characterization and modulation of immune stimulation by modified oligonucleotides",
<b>V</b>	٠	Antisense and Nucl. Acid Drug Dev. 7:4610461 (1997)

EXAMINER	DATE CONSIDERED			
12	10/15/02			
EVANINED 1911 1911 1911 1911 1911 1911 1911 19				

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. For, PTO-1449

## INFORMATION DISCLOSURE IN AN APPLICATION

Docket Number 106941.190 Application Number 09/760,506

Applicant
Charlotte Kensil

(Use several sheets if necessary)

Filing Date

Group Art Unit

Sheet

2

OF

2

01/12/2001

1632

	U	20,	•	CARSON, Dennis A. et al., "Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination, <i>J. Exp. Med</i> , 186:1621-1622 (1997)
				CHU, Rose et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity, <i>J. Exp. Med.</i> 186:1623-1632 (1997)
OLB F	30%	2		DALSGAARD, Kristian, "A study of the isolation and characterization of the saponin quil a", <i>Acta Veterinia</i> Scandinavica 69:1-40 (1978)
	2001	HCE		ELKINS, Karen L. et al., "Bacgerial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria", <i>J. Immunol</i> 162:2991-2298 (1999)
S. APR 1		3		FROEHLER, Brian, "Deoxynucleoside H-Phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues", <i>Tet. Let</i> 27:5575 (1986)
ATENT 8 T	ADEM		۴.	FROEHLER, Peter et al., "Synthesis of DNA via oleoxynucleoside H-phosphonate intermediates", <i>Nucl. Acid Res.</i> 14:5399-5407 (1986)
9			,	GAFFNEY, Barbara J et al., "Large-scale oligonucleotide synthesis by the H-Phosphonate method", <i>Tet. Let.</i> 29:2619-2622 (1988)
				GAREGG, Per J. et al., "Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach", <i>Tet. Let.</i> 27:4051-4054 (1986)
			•	GAREGG, Per J., et al., "Nuceloside H-Phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach" <i>Tet. Let.</i> 27:4055-4058 (1986)
			\	GOODCHILD, John, "Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties" <i>Bioconjugate Chem.</i> 1:165 (1990)
			4	HIGUCHI, Ryuichi et al., "Structure of desacylsaponins obtained from the bark of quillaja saponaria" <b>Phytochemistry</b> 26:229-235 (1987)
			•	KIRKBY, D.L. et al., "Effects of anticholinesterase drugs tacrine and E2020, the 5-HT₃ antagonist ondansetron, and the H₃ antagonist thioperamide, in models of cognition and cholinergic function
				KLINMAN, Dennis M., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ", <i>Proc. Natl. Acad. Sci USA</i> 93:2879-2883 (1996)
		Ì	ξ	KRIEG, Arthur M. et al., "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense and Nucl. Acid Drug Dev.</i> 6:133-139 (1996)
			,	KRIEG, Arthur M. et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to <i>listeria</i> monocytogenes challenge", <i>J. Immunol</i> 161:2428-2434 (1998)
		ĺ	,	MARCIANI, Dante J., et al., "Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats", <i>Vaccine</i> 9:89-96 (1991)
				NEWMAN, Mark J. et al., "Saponin adjuvant induction of ovalbumin-specific CD8 cytotoxic T lymphocyte responses", <i>J. Immunol.</i> 148:2357-2362 (1992)
			•	UHLMANN, Eugene et al. "Antisense oligonucleotides: A new therapeutic principle", Chem. Rev. 9:544-584 (1990)
		/	•	WEINER, George J et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motife are effective as immune adjuvants in tumor antigen immunization", <i>Proc. Natl. Acad. Sci.</i> 94:10833-10837 (1997)

EXAMINER	DATE CONSIDERED
Thee	10/15/02
ALAN ALL THE STATE OF THE STATE	

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.